Vera Therapeutics, Inc. - Schedule 13G Filing

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported beneficial ownership of 3,921,362 shares of Vera Therapeutics, Inc. common stock, representing 5.50% of the outstanding shares. This ownership was established as of March 11, 2026. The filing indicates that Deep Track Capital, LP is the primary reporting entity, with David Kroin identified as a control person. The shares were not acquired or held for the purpose of influencing the control of the issuer. The total outstanding common stock considered for this filing was 71,355,667 as of February 23, 2026. The filing also includes a joint filing statement, with David Kroin signing on behalf of all entities.